Sanofi to acquire Translate Bio shares for $38, representing equity value of $3.2 billion
( August 3, 2021, 15:37 GMT | Official Statement) -- MLex Summary: France-based Sanofi has agreed to acquire US-based Translate Bio, a clinical-stage messenger RNA therapeutics company, for $38 a share, representing a $3.2 billion equity value. The deal is expected to close in the third quarter of 2021. Both companies are traded on the Nasdaq. Statement follows in full: ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.